Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL646392 | 1.00 | HTR2A (0.43) | HTR2AHTR2CPDE7A | |
| Hydrochloric Acid SCHEMBL28659394 | 0.98 | HTR2A (0.46) | HTR2AHTR2CPDE7A | |
| SCHEMBL25155857 | 0.81 | HTR2A (0.34) | HTR2AHTR2CPDE7A | |
| SCHEMBL8518646 | 0.75 | CYP3A4 (0.43) | — | |
| SCHEMBL19814601 | 0.75 | ALOX15 (0.43) | — | |
| SCHEMBL14197705 | 0.73 | KDM1A (0.35) | — | |
| SCHEMBL24582723 | 0.73 | TAAR1 (0.37) | — | |
| SCHEMBL2336569 | 0.73 | HDAC4 (0.43) | — | |
| SCHEMBL23232266 | 0.73 | OPRL1 (0.42) | HTR2AHTR2CPDE7A | |
| SCHEMBL1604324 | 0.73 | HDAC4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642764-A2 | AZAINDOLE ROCK INHIBITORS | Avicenna Biosciences, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2024145569-A2 | AZAINDOLE ROCK INHIBITORS | AVICENNA BIOSCIENCES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HTR2A 2824/4885HTR2C 3584/4885PDE7A 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.